Results 151 to 160 of about 169,027 (313)

The ADESTE trial: A phase 2 study of enibarcimab, a monoclonal antibody targeting adrenomedullin, in acute heart failure

ESC Heart Failure, EarlyView.
Abstract Aims This study aimed to conduct a phase 2 proof‐of‐concept and safety study to evaluate the effect of ENIBARCIMAB (EN), a non‐neutralizing humanized monoclonal antibody targeting the N‐terminus of adrenomedullin (ADM), administered immediately after stabilization with standard of care (SoC) treatment, in patients hospitalized for acute heart ...
Anggoro Budi Hartopo, Arinal Chairul Achyar, Hendry Purnasidha Bagaswoto, Firandi Saputra, Hasanah Mumpuni, Dyah Adhi Kusumastuti, Teguh Triyono, Usi Sukorini, Metalia Puspitasari, Budi Yuli Setianto, Mohammad Saifur Rohman, Muhammad Anshory, Yoga Waranugraha, Putri Annisa Kamila, Agustin Iskandar, Hani Susianti, Andreas Bergman, Claudia Knothe, Paola Antonini, Salvatore Di Somma   +19 more
wiley   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

European Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo, Pietro Ameri, Aarti Asnani, Edoardo Bertero, Rudolf A. de Boer, Dimitrios Farmakis, Arantxa González, Stephane Heymans, Borja Ibáñez, Teresa López‐Fernández, Alexander R. Lyon, Piero Pollesello, Amina Rakisheva, Konstantinos Stellos, Katrin Streckfuss‐Bömeke, Carlo Gabriele Tocchetti, Thomas Thum, Peter van der Meer, Eva Van Rooij, Piotr Ponikowski, Marco Metra, Giuseppe Rosano, Sophie Van Linthout   +22 more
wiley   +1 more source

Role of antibody-based therapy in indolent non-Hodgkin's lymphoma

Leukemia Research Reports, 2021
Monoclonal antibodies (mAb) for indolent non-Hodgkin's lymphoma (iNHL) including follicular and marginal zone lymphomas was a key therapeutic development that changed the natural history of these diseases.
Patrick Willard, John McKay, Victor Yazbeck   +2 more
doaj  

Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy. [PDF]

, 2018
Anti-MAG demyelinating neuropathy is difficult to treat. All immunotherapies have failed except for rituximab, a chimeric B-cell–depleting monoclonal antibody against CD20, that helps up to 40% of patients based on 2 controlled and several uncontrolled ...
Dalakas, Marinos C., Martinez-Outshoorn, Ubaldo E., Rakocevic, Goran   +2 more
core   +1 more source

Subtle Alterations in Hippocampal Neuronal Activity Coincide With Early Sex‐Specific Differences in Amyloidosis and Microglia in a Pre‐Symptomatic Mouse Model of Alzheimer‐Like Pathology

Glia, EarlyView.
In a pre‐symptomatic mouse model of Alzheimer disease, despite higher amyloid‐β load, females display fewer plaques than males. More efficient synaptic transmission as well as less microgliosis point to better early coping with pathogenesis in females.
Thomas Chaigneau, Sha Sha, Candice M. Roux, Saba Aïd, Alice Faucher, Yannick Chantran, Guillaume Dorothée, Slavica Krantic   +7 more
wiley   +1 more source

Effects of omalizumab therapy on allergic rhinitis: a pilot study [PDF]

, 2016
The use of omalizumab, a humanized monoclonal antibody able to binding Ig-E, is currently authorized only for treatment of severe bronchial asthma. The use of omalizumab in other Ig-E related diseases is off-label, although some studies have provided ...
Begvarfaj, E, CAVALIERE, CARLO, MASIERI, Simonetta, MINNI, Antonio, ROSATI, DAVIDE   +4 more
core  

The study of pharmacodynamics of a medicine based on humanized monoclonal antibodies against IL-17 in rabbit model of antigen-induced arthritis

Биопрепараты: Профилактика, диагностика, лечение, 2018
The present article contains scientific data on the assessment of specific activity of therapeutic humanized monoclonal antibodies against IL-17 in rabbit model of antigen-induced arthritis.
A. A. Nedorubov, A. V. Grachev, M. A. Varavko, E. L. Morozova   +3 more
doaj  

Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis

IJU Case Reports, EarlyView.
ABSTRACT Introduction There is no clear evidence of the safety and efficacy of pembrolizumab plus lenvatinib combination therapy in patients on hemodialysis. This is the first report of a patient on hemodialysis to receive this combination therapy for metastatic renal cell carcinoma.
Shimpei Yamashita, Hiroki Kawabata, Yuya Iwahashi, Satoshi Muraoka, Takahito Wakamiya, Fumiyoshi Kojima, Yasuo Kohjimoto, Shin‐ichi Murata, Isao Hara   +8 more
wiley   +1 more source

Pregnancy outcomes after early fetal exposure to injectable first‐line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis

European Journal of Neurology, Volume 30, Issue 1, Page 162-171, January 2023., 2023
Abstract Background and purpose Data on pregnancy outcomes following fetal exposure to disease‐modifying drugs (DMDs) in women with multiple sclerosis (MS) are sparse although growing. Methods Data from the Danish Multiple Sclerosis Registry were linked with nationwide registries enabling an investigation of adverse pregnancy outcomes in newborns of ...
Johanna Balslev Andersen, Finn Sellebjerg, Melinda Magyari   +2 more
wiley   +1 more source

Leveraging Large Language Models to Predict Antibody Biological Activity Against Influenza A Hemagglutinin [PDF]

arXiv
Monoclonal antibodies (mAbs) represent one of the most prevalent FDA-approved modalities for treating autoimmune diseases, infectious diseases, and cancers. However, discovery and development of therapeutic antibodies remains a time-consuming and expensive process. Recent advancements in machine learning (ML) and artificial intelligence (AI) have shown
arxiv